Compare Cassava Sciences Inc (FLNA) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Synopsys, Inc. — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Synopsys, Inc. trades at $417.8 (market cap $81.43B). The key difference: Synopsys, Inc. is far larger — about 1532.4× Cassava Sciences Inc's market cap, and Synopsys, Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SNPS | |
|---|---|---|
Market Cap | $53.14M | $81.43B |
Sector | Health | Technology |
52-Week High | $4.64 | $645.59 |
52-Week Low | $1.09 | $380.47 |
Enterprise Value | -$33.43M | $89.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Synopsys (SNPS) trades at $423.37, down 0.57% on the day, with a bearish technical signal driven by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $3.68. Recent news highlights the company's strategic pivot toward AI-driven design tools and its role in the semiconductor ecosystem. Valuation ratios remain elevated, with a P/E of 97.32 and P/S of 8.98, reflecting high growth expectations.
The outlook for SNPS is supported by strong analyst sentiment, with 82.76% buy ratings and a consensus price target of $559.50, implying significant upside. However, risks include competitive pressures, execution challenges in integrating Ansys, and macroeconomic volatility affecting semiconductor demand. The stock's high valuation requires sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
